Core Viewpoint - The commercial challenges for Zhixiang Jintai (智翔金泰) are just beginning, despite significant revenue growth and reduced losses in 2025 [1][10]. Financial Performance - In 2025, Zhixiang Jintai achieved a revenue of 231 million yuan, a year-on-year increase of nearly 666.65% [2]. - The net loss for the company was 536 million yuan, which represents a 32.74% reduction in losses compared to the previous year [2][9]. - Operating cash flow net outflow significantly narrowed to 261 million yuan in the first three quarters of 2025, down from 423 million yuan in the same period of 2024, primarily due to sales collections and the receipt of upfront payments [7]. Product Development and Sales - The revenue growth was driven by two main factors: the sales volume of the first commercial product, Sailiqi monoclonal antibody (金立希®), and a one-time licensing income from overseas collaboration on GR1803 [3][4]. - Sailiqi monoclonal antibody generated sales revenue of 45.38 million yuan in the first half of 2025, contributing significantly to the total annual revenue of 230 million yuan [15]. - The product was included in the national medical insurance directory in December 2025, which is expected to enhance its market penetration by reducing patient out-of-pocket costs by over 60% [12]. Market Position and Competition - The IL-17A market is competitive, with six approved products in China, including Novartis' first-mover product, which poses a challenge for Zhixiang Jintai to maintain market share despite its lower pricing strategy [16]. - The company has a diversified pipeline that includes products for infectious diseases and oncology, with significant collaborations to alleviate financial pressure and leverage established distribution channels [17][19]. Strategic Approach - Zhixiang Jintai's strategy focuses on a combination of in-house development for autoimmune products and partnerships for infectious disease products, which helps control costs and mitigate risks [20]. - The company has demonstrated its ability to develop drugs and secure partnerships, but it now faces the challenge of proving its commercial viability and sustainability in the market [20]. Future Outlook - The high growth in 2025 is seen as just the beginning, with the real commercial challenges expected to unfold in 2026 [21].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The pharmaceutical excipients industry is entering a mature phase, with a focus on leading companies in pharmaceutical excipients [9] - The report highlights the increasing specialization and scale of the pharmaceutical excipients industry in China, driven by improved regulatory and standard systems [9][36] - The demand for plant-based capsules is expected to grow significantly, particularly in the Chinese market, with projections indicating a market size of approximately 423.7 billion yuan by 2027 [39] Summary by Sections Market Review - The pharmaceutical biotechnology index rose by 0.5% this week, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th in industry performance [14] - Year-to-date, the pharmaceutical biotechnology index has increased by 2.96%, outperforming the CSI 300 index by 1.21 percentage points, ranking 24th [14] Sub-industry Performance - Among sub-industries, biological products increased by 2.56%, medical devices by 2.16%, and pharmaceutical commerce by 1.13%, while chemical pharmaceuticals and medical services decreased by 0.64% and 0.99%, respectively [21] - The medical services sub-sector has shown the highest growth at 9.4% year-to-date, while chemical pharmaceuticals have the lowest growth with a decline of 1.65% [21] Key Company Announcements - Aibo Medical plans to acquire 68.31% of the shares of Demei Medical for approximately 6.83 billion yuan, with performance commitments set for the next three years [33] - GSK's new oral targeted drug, Linerixibat, has been accepted for market registration in China, aimed at treating primary biliary cholangitis [33] - Hansoh Pharmaceutical's new lung cancer drug, Amivantamab, has been approved for sale in the EU [34] Industry Trends - The report emphasizes the importance of pharmaceutical excipients in drug formulation and their impact on drug efficacy and manufacturing processes [36] - The new version of the Chinese Pharmacopoeia, effective from October 1, 2025, will enhance the quality of domestic pharmaceutical excipients and improve their competitiveness in international markets [36] - The market for plant-based capsules is expected to expand significantly, driven by the growth of the health supplement industry and the demand for high-quality pharmaceutical excipients [39]

Core Viewpoint - Novartis has received approval from the National Medical Products Administration for a new indication of secukinumab, which is now approved for treating adult patients with active radiographic axial spondyloarthritis (axSpA) who have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) [1] Group 1: Drug Approval and Indications - Secukinumab is now approved for its sixth indication in China, following approvals for severe plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa [1] - The newly approved indication targets axial spondyloarthritis (axSpA), a chronic inflammatory disease, specifically the early stage known as non-radiographic axial spondyloarthritis (nr-axSpA) [1] Group 2: Clinical Significance and Research - Patients with nr-axSpA typically start treatment with NSAIDs and physical therapy, but NSAIDs often only relieve symptoms without altering disease progression, leading to significant clinical and economic burdens due to delayed diagnosis [1] - Early diagnosis and treatment are crucial for improving clinical outcomes and reducing the burden on patients with nr-axSpA [1] - The PREVENT study, a global Phase III trial for secukinumab in nr-axSpA patients, demonstrated a higher ASAS40 response rate at week 16 compared to the placebo group, with improvements sustained until week 52 and good safety profile [1]

Core Viewpoint - Novartis' innovative biologic Cosentyx (secukinumab) has received approval from the National Medical Products Administration (NMPA) for a new indication to treat adult patients with active radiographic axial spondyloarthritis (nr-axSpA) who have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) [1][2] Group 1: Product Approval and Indications - The new indication for nr-axSpA is the sixth approved indication for Cosentyx in China, following approvals for moderate to severe plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa [1] - Cosentyx, an IL-17A inhibitor, specifically neutralizes IL-17A from various sources, alleviating symptoms of nr-axSpA and providing long-term benefits to patients [1] Group 2: Market Performance and Sales - Cosentyx has over 10 years of clinical experience in the axSpA, psoriasis, and psoriatic arthritis fields globally, supported by 5 years of long-term clinical research and real-world evidence [2] - Since its initial FDA approval in December 2014, Cosentyx achieved sales of $1.128 billion in 2016, with global sales projected to reach $6.141 billion in 2024, maintaining a double-digit growth rate of 23.31% [2] - In China, Cosentyx was approved in 2019, with the initial price set at 2,998 yuan per injection, which decreased to 1,188 yuan after being included in the medical insurance in 2020, and further to 870 yuan in 2023, leading to significant market success with sales reaching 4.092 billion yuan in 2023, capturing over 40% of the IL inhibitor market [2]

Core Viewpoint - The company, Lizhu Group, has announced that its core product, Lakanqita monoclonal antibody, has outperformed Secukinumab in the primary endpoint of a Phase III head-to-head clinical trial for moderate to severe psoriasis, with a PASI 100 response rate at week 12 [1] Group 1 - The product is the first IL-17A/F dual-target inhibitor in China, offering advantages such as less frequent dosing, convenient administration, and excellent safety profile [1] - The company has submitted for market approval and has been included in the CDE's priority review, with the earliest expected approval by the end of 2026 [1] - Cost competitive barriers have been established through the localization of raw materials and process optimization, laying a foundation for future market access and commercialization [1]

Drug Information - The drug "Lai Kang Qi Ta" monoclonal antibody injection has received acceptance for domestic production registration from the National Medical Products Administration (NMPA) [1] - It is classified as a Class 1 therapeutic biological product and is intended for adult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy [1] - The drug is a self-developed innovative IL-17A/F dual-target inhibitor, which is the first of its kind in China and the second globally [1][2] Clinical Development - A clinical trial for the drug is set to achieve primary and secondary efficacy endpoints by July 2025, demonstrating superior efficacy compared to the control group [1] - The trial results indicate faster onset, better short-term efficacy, long-lasting effects, and less frequent dosing compared to the control drug [1] - The cumulative R&D investment for the drug is approximately RMB 204.03 million [2] Market Situation - As of the announcement date, there are no approved products in China for psoriasis indications targeting the IL-17A/F dual-target [3] - There are three imported and two domestic products approved for IL-17A and IL-17RA single-target indications [3] - The estimated domestic terminal sales for IL-17A and IL-17RA single-target drugs in 2024 is RMB 2.833 billion [3]

Core Viewpoint - Lijun Pharmaceutical and Xinkanghe Biotech have submitted an application for the market approval of Lakanqita Monoclonal Antibody (LZM012/XKH004) for the treatment of plaque psoriasis [2] Group 1: Product Development - Lakanqita Monoclonal Antibody is an IL-17A/IL-17F monoclonal antibody that targets both homodimer IL-17A-A and IL-17F-F, as well as heterodimer IL-17A-F [4] - Lijun Pharmaceutical's subsidiary, Lijun Monoclonal Antibody, has exclusive rights for the global development, registration, production, sales, and sublicensing of this product [4] Group 2: Clinical Trial Results - In July, Lijun Pharmaceutical announced that Lakanqita Monoclonal Antibody (320mg, once every 4 weeks) met the primary endpoint in a Phase III clinical trial compared to Secukinumab (300mg, once every 4 weeks) for moderate to severe plaque psoriasis patients with or without psoriatic arthritis [4] - At week 12 of treatment, the proportion of patients achieving PASI 100 in the Lakanqita group was 49.5%, compared to 40.2% in the Secukinumab group, meeting both non-inferiority and superiority standards [4] - The overall safety profile of Lakanqita Monoclonal Antibody was good, with the incidence of common adverse events comparable to that of the control group [4]

Core Viewpoint - Lijun Pharmaceutical and Xinkanghe Biotech have submitted an application for the market approval of Lakanqita monoclonal antibody (LZM012/XKH004) for the treatment of plaque psoriasis [1] Group 1: Product Development - Lakanqita monoclonal antibody is an IL-17A/IL-17F monoclonal antibody that targets both homodimer IL-17A-A and IL-17F-F, as well as heterodimer IL-17A-F [2] - Lijun Pharmaceutical's subsidiary, Lijun Monoclonal Antibody, has obtained exclusive rights for the global development, registration, production, sales, and sublicensing of this product [2] Group 2: Clinical Trials - In July, Lijun Pharmaceutical announced that Lakanqita monoclonal antibody (320mg, once every 4 weeks) met the primary endpoint in a Phase III clinical trial compared to Secukinumab (300mg, once every 4 weeks) for moderate to severe plaque psoriasis patients with or without psoriatic arthritis [3] - At week 12 of treatment, the proportion of patients achieving PASI 100 in the Lakanqita group was 49.5%, compared to 40.2% in the Secukinumab group, meeting both non-inferiority and superiority standards [3] - The overall safety profile of Lakanqita monoclonal antibody was good, with the incidence of common adverse events comparable to that of the control group [3]

Core Viewpoint - He Mei Pharmaceutical is urgently seeking an IPO after 23 years of product development, with its first drug Mufemilast recently approved, amidst a highly competitive market for psoriasis treatments [1][4]. Company Overview - Founded in 2002, He Mei Pharmaceutical has raised over 1.2 billion yuan and incurred losses exceeding 1.1 billion yuan, achieving a valuation of 3.9 billion yuan without any products on the market [1][3]. - The company has been in a continuous state of high cash burn, with significant R&D expenditures primarily focused on Mufemilast, which has taken over 16 years to develop [2][3]. Product Development - Mufemilast's development timeline began in 2009, with clinical trials starting in 2012, and it received approval for treating moderate to severe plaque psoriasis in September 2025 [2]. - The R&D costs for Mufemilast accounted for 60% of the total R&D expenses from 2023 to mid-2025, reflecting the heavy investment required for its development [2]. Market Competition - The psoriasis drug market in China is highly competitive, with 18 approved targeted therapies, including 5 small molecules and 13 biologics, leading to a fierce price war [4][5]. - Major competitors include established products from international pharmaceutical giants, which have already captured significant market shares [4][5]. Pricing Strategy - He Mei Pharmaceutical plans to set Mufemilast's initial annual treatment cost between 52,700 and 119,900 yuan, positioning it above some small molecule competitors but below the price of leading biologics [7]. - The relatively high pricing strategy may hinder Mufemilast's competitiveness, especially among price-sensitive patients requiring long-term treatment [7][8]. Commercialization Challenges - The commercialization of Mufemilast is expected to be slow due to the nature of psoriasis as a chronic disease, which requires extensive academic promotion and trust-building among healthcare professionals [8]. - Even if Mufemilast successfully launches, it may not generate significant revenue quickly enough to offset the company's ongoing losses [8].

Core Viewpoint - He Mei Pharmaceutical is urgently seeking an IPO after 23 years of product development, with its first drug Mufemilast recently approved, amidst a highly competitive market for psoriasis treatments [1][6]. Company Overview - Founded in 2002, He Mei Pharmaceutical has raised over 1.2 billion RMB and incurred losses exceeding 1.1 billion RMB, achieving a valuation of 3.9 billion RMB despite having no products on the market [1][5]. - The company has been heavily reliant on external financing, completing six rounds of funding from 2021 to the end of 2024, with a post-investment valuation reaching 3.9 billion RMB after the E round [5]. Product Development - The development of Mufemilast has taken 16 years, starting from preclinical research in 2009 to receiving approval for treating moderate to severe plaque psoriasis in September 2025 [3]. - Research and development expenses for Mufemilast accounted for 60% of the total R&D costs, with losses reported at 156.4 million RMB for 2023 and projected losses of 123.4 million RMB for 2024 [3][4]. Market Competition - The psoriasis drug market in China is projected to grow from 18.2 billion RMB in 2024 to 48.3 billion RMB by 2028, with 18 approved targeted therapies already available, including 13 biologics [6][7]. - He Mei Pharmaceutical faces intense competition from established players like Novartis and Eli Lilly, which have already captured significant market shares with their products [6][7]. Pricing Strategy - He Mei Pharmaceutical plans to price Mufemilast between 52,700 RMB and 119,900 RMB annually, positioning it above some small molecule competitors but below the price of established biologics [8]. - The higher pricing strategy may hinder Mufemilast's competitiveness in a market where patients are sensitive to treatment costs, especially for chronic conditions requiring long-term medication [8][9]. Commercialization Challenges - The commercialization of Mufemilast is expected to be slow due to the need for long-term academic promotion and building trust among healthcare professionals [9]. - Even with successful market entry, Mufemilast is unlikely to generate significant revenue quickly, making it difficult for He Mei Pharmaceutical to reverse its overall loss situation [9].